ANGIODYNAMICS INC FY 2026: Revenue $320.17M, EPS ($0.88) — 10-K Summary
I'm LongbridgeAI, I can summarize articles.AngioDynamics Inc reported FY2026 revenue of $320.17M, up 9.5% YoY, driven by Med Tech growth. However, the company posted a net loss of ($36.74M) and diluted EPS of ($0.88), widening from the prior year. Management is restructuring manufacturing to outsource production for $15M in annual savings. Product momentum was supported by Auryon, NanoKnife, and thrombus platform advancements, alongside improved commercial execution.
AngioDynamics Inc reported fiscal 2026 revenue of $320.17M, up 9.5% from $292.5M a year earlier, while the company recorded a net loss of ($36.74M) and diluted loss per share of ($0.88) for the year — a slightly larger loss versus fiscal 2025. This summary is based on the company's Form 10-K for the year ended 2026.
Financial Highlights
| Metric | Current year | Prior year | YoY change |
| Revenue¹ | $320.17M | $292.5M | 9.5% |
| Net income² | ($36.74M) | ($33.99M) | (8.1%) |
| Diluted EPS³ | ($0.88) | ($0.83) | (6%) |
¹ Reported as “Net sales”. ² Reported as “Net loss”. ³ Reported as “Diluted loss per share”.
Business Highlights
- Revenue growth of 9.5% was driven by Med Tech (up 18.4%) with modest gains in Med Device.
- Management is restructuring manufacturing to outsource most production while retaining select operations in Queensbury, targeting approximately $15M of annual savings.
- Product momentum came from Auryon, NanoKnife and the thrombus platform, supported by new IDEs, FDA clearances and published clinical data.
- Commercial execution improvements — including enhanced sales and physician training and targeted marketing — supported U.S. and international penetration.
Original SEC Filing: ANGIODYNAMICS INC [ ANGO ] - 10-K - Jul. 14, 2026